High tea raises high hopes for TGen ovarian cancer research
PHOENIX, Ariz. - Feb. 16, 2009 - The Anne Rita Monahan Foundation will host Tea for Teal, a high English afternoon tea, to fund ovarian cancer research by the Translational Genomics Research Institute (TGen).
The Tea for Teal is at 2 p.m. Saturday, Feb. 28, at the Sheraton Downtown Phoenix, 340 N. Third St., part of the Anne Rita Monahan Foundation's efforts to raise $100,000 for ovarian cancer research.
Just as pink is the color representing the fight against breast cancer, teal is the color that represents the fight against ovarian cancer.
Funds will be used to research early-stage, drug-resistant ovarian cancer. TGen scientists are searching for a reliable early-screening tool and better drug treatments.
The Anne Rita Monahan Foundation was established by Anne Rita Monahan of Phoenix, a heroic ovarian cancer fighter, in an effort to warn other women about the disease, which she continues to fight daily.
Because the disease is often difficult to detect in its early stages, the Anne Rita Monahan Foundation is focused on education about the early signs and symptoms of ovarian cancer. The Foundation also funds research into the discovery of an effective, reliable screening tool that would help detect this type of cancer as soon as possible, giving women the best opportunities for remission.
The Anne Rita Monahan (ARM) Foundation's effort to eradicate ovarian cancer includes outreach and educational programs for the public and for the medical community. The Foundation urges women to "ARM Yourself Against Ovarian Cancer."
Anne Rita Monahan Foundation Tea for Teal
For more information or to register:
www.anneritamonahan.org or 602-264-5539.
Individual tickets are $60; a table of 10 is $500.
The Translational Genomics Research Institute (TGen) is a non-profit 501(c)(3) organization dedicated to the performance of groundbreaking research with life changing results. Research at TGen is focused on developing earlier diagnostics and smarter treatments for diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen's vision is of a world where an understanding of genomic variation can be rapidly translated to the diagnosis and treatment of disease in a manner tailored to individual patients.
Arizona Internet Marketing
Arizona Biotechnology Marketing